# Retatrutide References: Full Citation List with DOIs

> Full retatrutide reference list: Phase 1b, Phase 2 obesity, Phase 2 diabetes, Phase 2 liver disease, structural pharmacology, and 2025-2026 studies. DOIs and PubMed links.

Every cited source, with DOI or PubMed URL, organized numerically.

## Primary clinical trial studies

The peer-reviewed publications and registered trial results from which all quantitative claims on this site are drawn. DOIs and PubMed URLs are provided for each entry.

## References

[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
[2] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/
[3] Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[4] Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. https://pubmed.ncbi.nlm.nih.gov/36354040/
[5] Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
[6] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[7] Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological Insights. Med Sci (Basel). 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12372146/
[8] Appetite, eating attitudes, and eating behaviours during treatment with retatrutide. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/40916752/
[9] Jiang Y, et al. Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes? Diabetes Obes Metab. 2025;27(3):1079-1095. https://doi.org/10.1111/dom.16106
[10] Goetz IA, et al. Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. Obesity Pillars. 2025;16:100220. https://doi.org/10.1016/j.obpill.2025.100220
[11] Urva S, et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab. 2023;25(9):2784-2788. https://doi.org/10.1111/dom.15167
[12] Pardali EC, et al. New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication. Nutrients. 2026. https://doi.org/10.3390/nu18060962
[13] Briand F, et al. Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. Obesity (Silver Spring). 2026. https://doi.org/10.1002/oby.70155
[14] NCT06383390 — Cardiovascular outcomes trial for retatrutide (TRIUMPH cardiovascular/CKD program). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06383390
[15] Body composition substudy: retatrutide reduces lean body mass alongside fat mass in people with type 2 diabetes. Lancet Diabetes Endocrinol. 2025. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00092-0/abstract
[16] NCT05929066 — TRIUMPH Phase 3 active-comparator trial (retatrutide vs tirzepatide). NCT05931367 — TRIUMPH-3. NCT05882045 — TRANSCEND-CKD. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05929066
[17] Laroche ML, et al. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. Eur J Clin Pharmacol. 2026. https://doi.org/10.1007/s00228-026-04079-7

---

An editorial reading of the Phase 1–3 retatrutide record — every figure walked back to its trial, with no clinic behind the reading room and nothing here prescribed or sold.